U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Diffuse Midline Glioma, H3 K27M-Mutant

MedGen UID:
1791979
•Concept ID:
C5555538
•
Neoplastic Process

Definition

The reemergence of diffuse midline glioma, H3 K27M mutant, after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Diffuse Midline Glioma, H3 K27M-Mutant

Recent clinical studies

Etiology

Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
Odia Y, Hall MD, Cloughesy TF, Wen PY, Arrillaga-Romany I, Daghistani D, Mehta MP, Tarapore RS, Ramage SC, Allen JE
Neuro Oncol 2024 May 3;26(Supplement_2):S165-S172. doi: 10.1093/neuonc/noae021. PMID: 38386699Free PMC Article
Pulvinar Locus is Highly Relevant to Patients' Outcomes in Surgically Resected Thalamic Gliomas in Children.
Chiba K, Aihara Y, Masui K, Abe K, Komori T, Kawamata T
World Neurosurg 2020 Feb;134:e530-e539. Epub 2019 Nov 5 doi: 10.1016/j.wneu.2019.10.116. PMID: 31704359
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Chi AS, Tarapore RS, Hall MD, Shonka N, Gardner S, Umemura Y, Sumrall A, Khatib Z, Mueller S, Kline C, Zaky W, Khatua S, Weathers SP, Odia Y, Niazi TN, Daghistani D, Cherrick I, Korones D, Karajannis MA, Kong XT, Minturn J, Waanders A, Arillaga-Romany I, Batchelor T, Wen PY, Merdinger K, Schalop L, Stogniew M, Allen JE, Oster W, Mehta MP
J Neurooncol 2019 Oct;145(1):97-105. Epub 2019 Aug 27 doi: 10.1007/s11060-019-03271-3. PMID: 31456142Free PMC Article
Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.
Castel D, Philippe C, Calmon R, Le Dret L, Truffaux N, Boddaert N, Pagès M, Taylor KR, Saulnier P, Lacroix L, Mackay A, Jones C, Sainte-Rose C, Blauwblomme T, Andreiuolo F, Puget S, Grill J, Varlet P, Debily MA
Acta Neuropathol 2015 Dec;130(6):815-27. Epub 2015 Sep 23 doi: 10.1007/s00401-015-1478-0. PMID: 26399631Free PMC Article

Diagnosis

Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
Odia Y, Hall MD, Cloughesy TF, Wen PY, Arrillaga-Romany I, Daghistani D, Mehta MP, Tarapore RS, Ramage SC, Allen JE
Neuro Oncol 2024 May 3;26(Supplement_2):S165-S172. doi: 10.1093/neuonc/noae021. PMID: 38386699Free PMC Article
A Rare High-Grade Glioma with a Histone H3 K27M Mutation in the Hypothalamus of an Adult Patient.
He P, Chen W, Qiu XX, Xi YB, Guan H, Xia J
World Neurosurg 2019 Aug;128:527-531. Epub 2019 Apr 29 doi: 10.1016/j.wneu.2019.04.172. PMID: 31048046
Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.
Castel D, Philippe C, Calmon R, Le Dret L, Truffaux N, Boddaert N, Pagès M, Taylor KR, Saulnier P, Lacroix L, Mackay A, Jones C, Sainte-Rose C, Blauwblomme T, Andreiuolo F, Puget S, Grill J, Varlet P, Debily MA
Acta Neuropathol 2015 Dec;130(6):815-27. Epub 2015 Sep 23 doi: 10.1007/s00401-015-1478-0. PMID: 26399631Free PMC Article

Therapy

Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
Odia Y, Hall MD, Cloughesy TF, Wen PY, Arrillaga-Romany I, Daghistani D, Mehta MP, Tarapore RS, Ramage SC, Allen JE
Neuro Oncol 2024 May 3;26(Supplement_2):S165-S172. doi: 10.1093/neuonc/noae021. PMID: 38386699Free PMC Article
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.
Arrillaga-Romany I, Gardner SL, Odia Y, Aguilera D, Allen JE, Batchelor T, Butowski N, Chen C, Cloughesy T, Cluster A, de Groot J, Dixit KS, Graber JJ, Haggiagi AM, Harrison RA, Kheradpour A, Kilburn LB, Kurz SC, Lu G, MacDonald TJ, Mehta M, Melemed AS, Nghiemphu PL, Ramage SC, Shonka N, Sumrall A, Tarapore RS, Taylor L, Umemura Y, Wen PY
J Clin Oncol 2024 May 1;42(13):1542-1552. Epub 2024 Feb 9 doi: 10.1200/JCO.23.01134. PMID: 38335473Free PMC Article
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Chi AS, Tarapore RS, Hall MD, Shonka N, Gardner S, Umemura Y, Sumrall A, Khatib Z, Mueller S, Kline C, Zaky W, Khatua S, Weathers SP, Odia Y, Niazi TN, Daghistani D, Cherrick I, Korones D, Karajannis MA, Kong XT, Minturn J, Waanders A, Arillaga-Romany I, Batchelor T, Wen PY, Merdinger K, Schalop L, Stogniew M, Allen JE, Oster W, Mehta MP
J Neurooncol 2019 Oct;145(1):97-105. Epub 2019 Aug 27 doi: 10.1007/s11060-019-03271-3. PMID: 31456142Free PMC Article

Prognosis

Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
Odia Y, Hall MD, Cloughesy TF, Wen PY, Arrillaga-Romany I, Daghistani D, Mehta MP, Tarapore RS, Ramage SC, Allen JE
Neuro Oncol 2024 May 3;26(Supplement_2):S165-S172. doi: 10.1093/neuonc/noae021. PMID: 38386699Free PMC Article
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.
Arrillaga-Romany I, Gardner SL, Odia Y, Aguilera D, Allen JE, Batchelor T, Butowski N, Chen C, Cloughesy T, Cluster A, de Groot J, Dixit KS, Graber JJ, Haggiagi AM, Harrison RA, Kheradpour A, Kilburn LB, Kurz SC, Lu G, MacDonald TJ, Mehta M, Melemed AS, Nghiemphu PL, Ramage SC, Shonka N, Sumrall A, Tarapore RS, Taylor L, Umemura Y, Wen PY
J Clin Oncol 2024 May 1;42(13):1542-1552. Epub 2024 Feb 9 doi: 10.1200/JCO.23.01134. PMID: 38335473Free PMC Article
Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma.
Vaubel RA, Tian S, Remonde D, Schroeder MA, Mladek AC, Kitange GJ, Caron A, Kollmeyer TM, Grove R, Peng S, Carlson BL, Ma DJ, Sarkar G, Evers L, Decker PA, Yan H, Dhruv HD, Berens ME, Wang Q, Marin BM, Klee EW, Califano A, LaChance DH, Eckel-Passow JE, Verhaak RG, Sulman EP, Burns TC, Meyer FB, O'Neill BP, Tran NL, Giannini C, Jenkins RB, Parney IF, Sarkaria JN
Clin Cancer Res 2020 Mar 1;26(5):1094-1104. Epub 2019 Dec 18 doi: 10.1158/1078-0432.CCR-19-0909. PMID: 31852831Free PMC Article
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Chi AS, Tarapore RS, Hall MD, Shonka N, Gardner S, Umemura Y, Sumrall A, Khatib Z, Mueller S, Kline C, Zaky W, Khatua S, Weathers SP, Odia Y, Niazi TN, Daghistani D, Cherrick I, Korones D, Karajannis MA, Kong XT, Minturn J, Waanders A, Arillaga-Romany I, Batchelor T, Wen PY, Merdinger K, Schalop L, Stogniew M, Allen JE, Oster W, Mehta MP
J Neurooncol 2019 Oct;145(1):97-105. Epub 2019 Aug 27 doi: 10.1007/s11060-019-03271-3. PMID: 31456142Free PMC Article
Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.
Castel D, Philippe C, Calmon R, Le Dret L, Truffaux N, Boddaert N, Pagès M, Taylor KR, Saulnier P, Lacroix L, Mackay A, Jones C, Sainte-Rose C, Blauwblomme T, Andreiuolo F, Puget S, Grill J, Varlet P, Debily MA
Acta Neuropathol 2015 Dec;130(6):815-27. Epub 2015 Sep 23 doi: 10.1007/s00401-015-1478-0. PMID: 26399631Free PMC Article

Clinical prediction guides

Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
Odia Y, Hall MD, Cloughesy TF, Wen PY, Arrillaga-Romany I, Daghistani D, Mehta MP, Tarapore RS, Ramage SC, Allen JE
Neuro Oncol 2024 May 3;26(Supplement_2):S165-S172. doi: 10.1093/neuonc/noae021. PMID: 38386699Free PMC Article
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.
Arrillaga-Romany I, Gardner SL, Odia Y, Aguilera D, Allen JE, Batchelor T, Butowski N, Chen C, Cloughesy T, Cluster A, de Groot J, Dixit KS, Graber JJ, Haggiagi AM, Harrison RA, Kheradpour A, Kilburn LB, Kurz SC, Lu G, MacDonald TJ, Mehta M, Melemed AS, Nghiemphu PL, Ramage SC, Shonka N, Sumrall A, Tarapore RS, Taylor L, Umemura Y, Wen PY
J Clin Oncol 2024 May 1;42(13):1542-1552. Epub 2024 Feb 9 doi: 10.1200/JCO.23.01134. PMID: 38335473Free PMC Article
Pulvinar Locus is Highly Relevant to Patients' Outcomes in Surgically Resected Thalamic Gliomas in Children.
Chiba K, Aihara Y, Masui K, Abe K, Komori T, Kawamata T
World Neurosurg 2020 Feb;134:e530-e539. Epub 2019 Nov 5 doi: 10.1016/j.wneu.2019.10.116. PMID: 31704359
A Rare High-Grade Glioma with a Histone H3 K27M Mutation in the Hypothalamus of an Adult Patient.
He P, Chen W, Qiu XX, Xi YB, Guan H, Xia J
World Neurosurg 2019 Aug;128:527-531. Epub 2019 Apr 29 doi: 10.1016/j.wneu.2019.04.172. PMID: 31048046
Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.
Castel D, Philippe C, Calmon R, Le Dret L, Truffaux N, Boddaert N, Pagès M, Taylor KR, Saulnier P, Lacroix L, Mackay A, Jones C, Sainte-Rose C, Blauwblomme T, Andreiuolo F, Puget S, Grill J, Varlet P, Debily MA
Acta Neuropathol 2015 Dec;130(6):815-27. Epub 2015 Sep 23 doi: 10.1007/s00401-015-1478-0. PMID: 26399631Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...